Tear Solutions Raises $15 Million

Represented TearSolutions, a developer of a peptide therapy for the treatment of dry eye in primary sjögren's syndrome patients, raised $15.71 million through the combination of Series B-3-1, Series B-3-2 and Series B-3-3 venture funding in a deal led by VTC Ventures, putting the company's pre-money valuation at $42.29 million. Virginia Innovation Partnership Corporation, Dave Metzak, Jim Cheng, and other undisclosed investors also participated in the round.